Targeted therapy for non-small cell lung cancer has welcomed new targets, bringing treatment opportunities to more patients. Testing needs to identify specific mutation subtypes to match corresponding drugs, and some drugs have been included in local medical insurance coverage.
Significance of new targets
The key to lung cancer treatment lies in precise matching. The discovery of new targets means more patients with driver gene positivity can access corresponding targeted drugs, shifting from traditional chemotherapy to more precise treatment with fewer side effects.
Importance of testing
The premise of targeted therapy is accurate gene testing. Patients should complete gene testing covering common and emerging targets at regulated institutions, and choose corresponding drugs after identifying specific mutation subtypes.
Cost and accessibility
Some targeted drugs have been included in local medical insurance coverage, significantly reducing patients' out-of-pocket burden. Specific reimbursement policies vary by region and can be consulted with medical advisors.
MedBridge services
Overseas patients can submit gene reports through remote consultation. MedBridge assists with medication evaluation at partner hospitals, and costs can be checked through cost estimation.